
Physician Reports: Enhanced Report on Diabetes and Chronic Kidney Disease
Endocrinology & Diabetes, Primary Care / Family Medicine
2022-09-01 – Present
To address the growing complexity of managing T2D alongside serious cardiac and renal comorbidities, PLP Medical Director Dr. Donna Manca continues to collaborate with NAPCReN on this initiative to help optimize high-impact prescribing. Because these comorbidities significantly elevate the risk of mortality and organ failure, PCPs are advised to use the newest therapeutic agents recommended by Diabetes Canada, specifically sodium–glucose cotransporter 2 inhibitors (SGLT2i). This project leverages CPCSSN data to move beyond basic monitoring, providing physicians with a sophisticated look at how often these SGLT2i medications are being prescribed to their highest-risk patients.
By translating complex prescribing data into individualized, benchmarked feedback, the initiative empowers clinicians to bridge the gap between evolving clinical guidelines and daily practice. The 2025–2026 cycle delivered updated reports to 86 physician sentinels, bringing the total to 312 reports distributed since 2022–23. To ensure these insights are immediately actionable, the reports include a comprehensive educational suite, with recordings from diabetes-focused learning events, including Team up for health: Integrating diabetes and kidney care, Your Diabetes Dilemmas: Comment on real life cases; and From sugar highs to fat fries: The latest in diabetes and lipid management; and Beyond blood sugar: Pearls for practice. This data-driven approach ensures that Albertans with complex diabetes receive the most advanced care available to improve their long-term survival and quality of life.
By providing a clear view of prescribing patterns for high-risk patients, these reports help physicians translate data into action, supporting organ-preserving care and improving access to evidence-based therapies for those who need them most.